Endothelial Nitric Oxide Synthase Gene Therapy for Erectile Dysfunction

Author(s): Trinity J. Bivalacqua, Biljana Musicki, Mustafa F. Usta, Hunter C. Champion, Philip J. Kadowitz, Arthur L. Burnett, Wayne J.G. Hellstrom

Journal Name: Current Pharmaceutical Design

Volume 11 , Issue 31 , 2005

Become EABM
Become Reviewer
Call for Editor


Basic science research on erectile physiology has been devoted to investigating the pathogenesis of erectile dysfunction (ED) and has led to the conclusion that ED is predominately a disease of vascular origin. It is well recognized that the incidence of ED dramatically increases in men who suffer from diabetes mellitus, hypercholesterolemia, and cardiovascular disease. Endothelial nitric oxide synthase (eNOS) is an important factor in cardiovascular homeostasis, angiogenesis, and erectile function. Given the impact of endothelial-derived nitric oxide (NO) in vascular biology, a great deal of research over the past decade has focused on the role of NO synthesis from the endothelium in normal erectile physiology as well as in disease states. Loss of the functional integrity of the endothelium and subsequent endothelial dysfunction plays an integral role in the occurrence of ED. Therefore, a likely target of gene therapy for the treatment of ED is eNOS. This communication reviews the role of eNOS in erectile physiology and discusses the alterations in eNOS expression in various vascular diseases of the penis. Putative gene therapy interventions to restore eNOS expression and subsequent endothelial function may represent an exciting new therapeutic strategy for the future treatment of ED.

Keywords: eNOS, nitric oxide, corpus cavernosum, gene transfer, diabetes, aging

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Published on: 01 March, 2012
Page: [4059 - 4067]
Pages: 9
DOI: 10.2174/138161205774913345
Price: $65

Article Metrics

PDF: 3